Should HFrEF patients with NYHA class II expect benefit from CCM therapy?: Results from the MAINTAINED observational study
Background: Cardiac contractility modulation (CCM) is an FDA-approved device therapy for patients with refractory systolic heart failure and normal QRS width. Randomized trials demonstrated benefits of CCM primarily for patients with severe heart failure (> NYHA class II). Purpose: To better unde...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
3 September 2022
|
| In: |
Clinical research in cardiology
Year: 2022, Jahrgang: 111, Heft: 11, Pages: 1286-1294 |
| ISSN: | 1861-0692 |
| DOI: | 10.1007/s00392-022-02089-w |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00392-022-02089-w Verlag, lizenzpflichtig, Volltext: https://link.springer.com/content/pdf/10.1007/s00392-022-02089-w.pdf?pdf=button 
|
| Verfasserangaben: | Christian Fastner, Goekhan Yuecel, Svetlana Hetjens, Boris Rudic, Gereon Schmiel, Matthias Toepel, Volker Liebe, Mathieu Kruska, Martin Borggrefe, Daniel Burkhoff, Ibrahim Akin, Daniel Duerschmied, Juergen Kuschyk |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1852268670 | ||
| 003 | DE-627 | ||
| 005 | 20240307090507.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230710s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00392-022-02089-w |2 doi | |
| 035 | |a (DE-627)1852268670 | ||
| 035 | |a (DE-599)KXP1852268670 | ||
| 035 | |a (OCoLC)1425217376 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Fastner, Christian |d 1985- |e VerfasserIn |0 (DE-588)1075156661 |0 (DE-627)832943770 |0 (DE-576)443267634 |4 aut | |
| 245 | 1 | 0 | |a Should HFrEF patients with NYHA class II expect benefit from CCM therapy? |b Results from the MAINTAINED observational study |c Christian Fastner, Goekhan Yuecel, Svetlana Hetjens, Boris Rudic, Gereon Schmiel, Matthias Toepel, Volker Liebe, Mathieu Kruska, Martin Borggrefe, Daniel Burkhoff, Ibrahim Akin, Daniel Duerschmied, Juergen Kuschyk |
| 246 | 3 | 3 | |a Should HFrEF patients with NYHA class two expect benefit from CCM therapy? |
| 264 | 1 | |c 3 September 2022 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.07.2023 | ||
| 520 | |a Background: Cardiac contractility modulation (CCM) is an FDA-approved device therapy for patients with refractory systolic heart failure and normal QRS width. Randomized trials demonstrated benefits of CCM primarily for patients with severe heart failure (> NYHA class II). Purpose: To better understand individualized indication in clinical practice, we compared the effect of CCM in patients with baseline NYHA class II vs. NYHA class III or ambulatory IV over the 5-year period in our large clinical registry (MAINTAINED Observational Study). Methods: Changes in NYHA class, left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE), NT-proBNP level, and KDIGO chronic kidney disease stage were compared as functional parameters. In addition, mortality within 3 years was compared with the prediction of the Meta-Analysis Global Group in Chronic heart failure risk score. Results: A total of 172 patients were included in the analyses (10% with NYHA class II). Only patients with NYHA class III/IV showed a significant improvement in NYHA class over 5 years of CCM (II: 0.1 ± 0.6; p = 0.96 vs. III/IV: − 0.6 ± 0.6; p < 0.0001). In both groups, LVEF improved significantly (II: 4.7 ± 8.3; p = 0.0072 vs. III/IV: 7.0 ± 10.7%; p < 0.0001), while TAPSE improved significantly only in NYHA class III/IV patients (II: 2.2 ± 1.6; p = 0.20 vs. III/IV: 1.8 ± 5.2 mm; p = 0.0397). LVEF improvement was comparable in both groups over 5 years of CCM (p = 0.83). NYHA class II patients had significantly lower NT-proBNP levels at baseline (858 [175/6887] vs. 2632 [17/28830] ng/L; p = 0.0044), which was offset under therapy (399 [323/1497] vs. 901 [13/18155] ng/L; p = 0.61). Actual 3-year mortality was 17 and 26% vs. a predicted mortality of 31 and 42%, respectively (p = 0.0038 for NYHA class III/IV patients). Conclusions: NYHA class III/IV patients experienced more direct and extensive functional improvements with CCM and a survival benefit compared with the predicted risk. However, our data suggest that NYHA class II patients may also benefit from the sustained positive effects of LVEF improvement. | ||
| 650 | 4 | |a Cardiac contractility modulation | |
| 650 | 4 | |a Cardiac remodeling | |
| 650 | 4 | |a Cardiomyopathy | |
| 650 | 4 | |a Device therapy | |
| 650 | 4 | |a Left ventricular ejection fraction | |
| 650 | 4 | |a Tricuspid annular plane systolic excursion | |
| 700 | 1 | |a Yücel, Gökhan |d 1985- |e VerfasserIn |0 (DE-588)1123528063 |0 (DE-627)876733259 |0 (DE-576)481781145 |4 aut | |
| 700 | 1 | |a Hetjens, Svetlana |d 1983- |e VerfasserIn |0 (DE-588)1031801979 |0 (DE-627)737600284 |0 (DE-576)379534223 |4 aut | |
| 700 | 1 | |a Rudic, Boris |d 1982- |e VerfasserIn |0 (DE-588)1024726789 |0 (DE-627)720427134 |0 (DE-576)369410599 |4 aut | |
| 700 | 1 | |a Schmiel, Gereon |d 1996- |e VerfasserIn |0 (DE-588)1295558351 |0 (DE-627)1852269243 |4 aut | |
| 700 | 1 | |a Toepel, Matthias |d 1989- |e VerfasserIn |0 (DE-588)1295558602 |0 (DE-627)1852269502 |4 aut | |
| 700 | 1 | |a Liebe, Volker |d 1976- |e VerfasserIn |0 (DE-588)124795757 |0 (DE-627)366425102 |0 (DE-576)294506926 |4 aut | |
| 700 | 1 | |a Kruska, Mathieu |d 1983- |e VerfasserIn |0 (DE-588)1156360382 |0 (DE-627)1019154055 |0 (DE-576)502145439 |4 aut | |
| 700 | 1 | |a Borggrefe, Martin |e VerfasserIn |0 (DE-588)1025920546 |0 (DE-627)725574232 |0 (DE-576)370913426 |4 aut | |
| 700 | 1 | |a Burkhoff, Daniel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Akın, Ibrahim |d 1978- |e VerfasserIn |0 (DE-588)132322293 |0 (DE-627)521039010 |0 (DE-576)299074366 |4 aut | |
| 700 | 1 | |a Dürschmied, Daniel |d 1976- |e VerfasserIn |0 (DE-588)129152196 |0 (DE-627)390022462 |0 (DE-576)187844623 |4 aut | |
| 700 | 1 | |a Kuschyk, Jürgen |d 1968- |e VerfasserIn |0 (DE-588)122441850 |0 (DE-627)081944993 |0 (DE-576)293272212 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical research in cardiology |d Berlin : Springer, 2006 |g 111(2022), 11 vom: Nov., Seite 1286-1294 |h Online-Ressource |w (DE-627)506287343 |w (DE-600)2218331-0 |w (DE-576)251097692 |x 1861-0692 |7 nnas |a Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study |
| 773 | 1 | 8 | |g volume:111 |g year:2022 |g number:11 |g month:11 |g pages:1286-1294 |g extent:9 |a Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational study |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00392-022-02089-w |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/content/pdf/10.1007/s00392-022-02089-w.pdf?pdf=button |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230710 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 122441850 |a Kuschyk, Jürgen |m 122441850:Kuschyk, Jürgen |d 60000 |e 60000PK122441850 |k 0/60000/ |p 13 |y j | ||
| 998 | |g 129152196 |a Dürschmied, Daniel |m 129152196:Dürschmied, Daniel |d 60000 |d 61000 |e 60000PD129152196 |e 61000PD129152196 |k 0/60000/ |k 1/60000/61000/ |p 12 | ||
| 998 | |g 132322293 |a Akın, Ibrahim |m 132322293:Akın, Ibrahim |d 60000 |d 61000 |e 60000PA132322293 |e 61000PA132322293 |k 0/60000/ |k 1/60000/61000/ |p 11 | ||
| 998 | |g 1025920546 |a Borggrefe, Martin |m 1025920546:Borggrefe, Martin |d 60000 |d 61000 |e 60000PB1025920546 |e 61000PB1025920546 |k 0/60000/ |k 1/60000/61000/ |p 9 | ||
| 998 | |g 1156360382 |a Kruska, Mathieu |m 1156360382:Kruska, Mathieu |d 50000 |e 50000PK1156360382 |k 0/50000/ |p 8 | ||
| 998 | |g 124795757 |a Liebe, Volker |m 124795757:Liebe, Volker |d 60000 |e 60000PL124795757 |k 0/60000/ |p 7 | ||
| 998 | |g 1295558602 |a Toepel, Matthias |m 1295558602:Toepel, Matthias |d 60000 |e 60000PT1295558602 |k 0/60000/ |p 6 | ||
| 998 | |g 1295558351 |a Schmiel, Gereon |m 1295558351:Schmiel, Gereon |d 60000 |e 60000PS1295558351 |k 0/60000/ |p 5 | ||
| 998 | |g 1024726789 |a Rudic, Boris |m 1024726789:Rudic, Boris |d 60000 |d 61000 |e 60000PR1024726789 |e 61000PR1024726789 |k 0/60000/ |k 1/60000/61000/ |p 4 | ||
| 998 | |g 1031801979 |a Hetjens, Svetlana |m 1031801979:Hetjens, Svetlana |d 60000 |d 60200 |d 60250 |e 60000PH1031801979 |e 60200PH1031801979 |e 60250PH1031801979 |k 0/60000/ |k 1/60000/60200/ |k 2/60000/60200/60250/ |p 3 | ||
| 998 | |g 1123528063 |a Yücel, Gökhan |m 1123528063:Yücel, Gökhan |p 2 | ||
| 998 | |g 1075156661 |a Fastner, Christian |m 1075156661:Fastner, Christian |d 60000 |d 61000 |e 60000PF1075156661 |e 61000PF1075156661 |k 0/60000/ |k 1/60000/61000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1852268670 |e 4351776161 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Christian Fastner, Goekhan Yuecel, Svetlana Hetjens, Boris Rudic, Gereon Schmiel, Matthias Toepel, Volker Liebe, Mathieu Kruska, Martin Borggrefe, Daniel Burkhoff, Ibrahim Akin, Daniel Duerschmied, Juergen Kuschyk"]},"person":[{"family":"Fastner","role":"aut","display":"Fastner, Christian","given":"Christian"},{"display":"Yücel, Gökhan","given":"Gökhan","family":"Yücel","role":"aut"},{"family":"Hetjens","role":"aut","given":"Svetlana","display":"Hetjens, Svetlana"},{"display":"Rudic, Boris","given":"Boris","role":"aut","family":"Rudic"},{"family":"Schmiel","role":"aut","display":"Schmiel, Gereon","given":"Gereon"},{"role":"aut","family":"Toepel","given":"Matthias","display":"Toepel, Matthias"},{"role":"aut","family":"Liebe","given":"Volker","display":"Liebe, Volker"},{"given":"Mathieu","display":"Kruska, Mathieu","role":"aut","family":"Kruska"},{"display":"Borggrefe, Martin","given":"Martin","role":"aut","family":"Borggrefe"},{"role":"aut","family":"Burkhoff","given":"Daniel","display":"Burkhoff, Daniel"},{"display":"Akın, Ibrahim","given":"Ibrahim","role":"aut","family":"Akın"},{"role":"aut","family":"Dürschmied","display":"Dürschmied, Daniel","given":"Daniel"},{"display":"Kuschyk, Jürgen","given":"Jürgen","family":"Kuschyk","role":"aut"}],"recId":"1852268670","id":{"doi":["10.1007/s00392-022-02089-w"],"eki":["1852268670"]},"physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"Should HFrEF patients with NYHA class II expect benefit from CCM therapy?","subtitle":"Results from the MAINTAINED observational study","title":"Should HFrEF patients with NYHA class II expect benefit from CCM therapy?"}],"origin":[{"dateIssuedDisp":"3 September 2022","dateIssuedKey":"2022"}],"relHost":[{"recId":"506287343","pubHistory":["95.2006 -"],"language":["eng"],"part":{"volume":"111","year":"2022","text":"111(2022), 11 vom: Nov., Seite 1286-1294","issue":"11","extent":"9","pages":"1286-1294"},"origin":[{"dateIssuedKey":"2006","publisherPlace":"Berlin","publisher":"Springer","dateIssuedDisp":"2006-"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Should HFrEF patients with NYHA class II expect benefit from CCM therapy? Results from the MAINTAINED observational studyClinical research in cardiology","title":[{"title":"Clinical research in cardiology","title_sort":"Clinical research in cardiology"}],"id":{"zdb":["2218331-0"],"eki":["506287343"],"issn":["1861-0692"]},"physDesc":[{"extent":"Online-Ressource"}]}],"language":["eng"],"note":["Gesehen am 10.07.2023"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"titleAlt":[{"title":"Should HFrEF patients with NYHA class two expect benefit from CCM therapy?"}]} | ||
| SRT | |a FASTNERCHRSHOULDHFRE3202 | ||